AI enhanced lifetime-based mesoscopic in vivo imaging of tissue molecular heterogeneity

Active Project Grant Awarded Jun 1, 2023 Last action May 19, 2026

Award ID: R01CA271371
Recipient: Rensselaer Polytechnic Institute UEI U5WBFKEBLMX3
Awarding agency: National Cancer Institute National Institutes of Health, Department of Health and Human Services
Obligated: $3,859,957

Award facts

Award details come from USAspending.gov.

As the agency reported it.

Abstract: Quantification of drug-target engagement is recognized as the most crucial parameter in the drug development pipeline as IT is central to therapeutic action. Though, such parameter can only be assessed via invasive biochemical and immunohistochemical (IHC) approaches in EX vivo tissues. Herein, we propose to integrate and optimize a multimodal optical imaging platform that can provide direct longitudinal (multiple time points) measurements of the drug-target engagement distribution across the same tissue volume in correlation with drug delivery efficacy parameters, including, tumor vasculature, and indicators of drug response, such as metabolism. The imaging platform will be validated in human breast tumor and patient derived xenografts in live animals subjected to HER2-trastuzumab therapy. Additionally, as mfmt is an indirect image formation technique relying on complex computational tasks, we will further pioneer the use of deep learning methodologies for fast, accurate, parameter-free and user friendly 2D and 3D mfmt image formation.

Subrecipient	Amount	Awarded
Albany Med Health System Herein, a synergistic collaborative team of AMC and RPI researchers proposes to improve non-invasive imaging methodology to assess intra-tumor heterogeneities…	$1,329,388	Jun 17, 2026

R01CA271371 was awarded to Rensselaer Polytechnic Institute by National Cancer Institute (National Institutes of Health) on June 1, 2023.

$3,859,957 has been obligated on R01CA271371.

On GovTribe

Try for free Login